P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115488 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Fani Koutsougianni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinogenesis, Molecular Targeted Therapy, Ribosomal Protein S6 Kinases, 90-kDa. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 197 Literaturangaben.
Abstract (Originalsprache)
The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have occurred, such as biological insights, function, and mechanisms associated with carcinogenesis. We additionally present and discuss the recent advances but also the limitations in the development of pharmacological inhibitors of RSKs, in the context of the use of these kinases as putative, more efficient targets for novel anticancer therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece.
- Department of Histology and Embryology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34500 Istanbul, Turkey.
- Dept of Translational Medicine, Medical Faculty, Lund University and Center for Molecular Pathology, Skäne University Hospital, Jan Waldenströms gata 59, SE 205 02 Malmö, Sweden.
- Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece. Electronic address: kdimas@uth.gr.
Zitieren
APA
Koutsougianni, F., Alexopoulou, D., Uvez, A., Lamprianidou, A., Sereti, E., Tsimplouli, C., Ilkay Armutak, E., & Dimas, K. (2023). P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115488
Vancouver
Koutsougianni F, Alexopoulou D, Uvez A, Lamprianidou A, Sereti E, Tsimplouli C, et al. P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115488
BibTeX
@article{Koutsougianni2023,
author = {Koutsougianni, Fani and Alexopoulou, Dimitra and Uvez, Ayca and Lamprianidou, Andromachi and Sereti, Evangelia and Tsimplouli, Chrisiida and Ilkay Armutak, Elif and Dimas, Konstantinos},
title = {P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115488}
}
EUVIMED